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ABSTRACT Recently we isolated a protein growth factor
of 34 kDa from trophoblastic membranes of human placenta.
A fraction (,50%) of the membrane-associated 34-kDa pro-
tein is peripherally associated-i.e., it can be released by high
salt treatment. The remainder shows the characteristics of an
integral membrane protein-i.e., its release requires detergent
treatment. Here we report studies on the structural basis for
membrane anchorage of the protein. Phospholipase C was
found to release an immunoreactive 34-kDa polypeptide from
intact isolated cytotrophoblasts. Studies with isolated tropho-
blastic membranes showed that phospholipase C specifically
released the salt-resistant fraction of the 34-kDa polypeptide.
The polypeptide released by phospholipase C showed the same
electrophoretic mobility in NaDodS04/PAGE as the polypep-
tide prior to phospholipase C treatment. The identity of the
released protein with the 34-kDa growth factor has been
established by both immunologic and receptor-binding assays.
Other studies show that there is biosynthetic incorporation of
[3H]myristate into the 34-kDa protein. The myristate label is
labile to phospholipase C treatment. These results suggest that
some of the 34-kDa protein is anchored to the plasma mem-
brane via a posttranslationally added phospholipid. This mode
of anchorage has been observed for some other membrane
proteins and raises interesting questions regarding the role of
this novel linkage in the mitogenic function of the 34-kDa
polypeptide.
an integral membrane protein-i.e., its release requires de-
tergent treatment.
What could be the structural basis for membrane anchor-
age of the salt-resistant protein? The identical mobilities of
the salt-released and salt-resistant polypeptides in NaDod-
S04/PAGE discounts the possibility of anchorage to mem-
brane through a protein segment. Also, studies on biosyn-
thesis and turnover of the protein in isolated cytotropho-
blasts reveal only one immunoreactive product of 34 kDa in
NaDodSO4/PAGE (7). In the light of these findings, we
considered the possibility of anchorage through lipids. In
recent years a number of membrane proteins have been
shown to be anchored to the membrane through posttrans-
lationally added lipids. This mode of anchorage has been
confirmed for alkaline phosphatase, Thy-1 antigen, T cell-
activating protein, and the surface glycoproteins of trypano-
somes (5, 6). We tested whether the 34-kDa growth factor
belongs to this category of membrane proteins. The studies
described here show that phospholipase C can release the
protein from both intact cytotrophoblasts and isolated plas-
ma membranes and that it releases the salt-resistant fraction
of the protein. These results suggest that some of the 34-kDa
protein is anchored to the plasma membrane via a posttrans-
lationally added phospholipid. This finding raises interesting
questions regarding the role of this novel anchorage in the
mitogenic function of the 34-kDa protein.
Human placenta contains a growth factor of molecular mass
34,000 that is different from other known placental and
nonplacental factors in its antigenic structure, receptor bind-
ing specificity, and membrane-association behavior (1-3).
Although it is an extracellular protein that exerts its effects
upon target cells through a specific surface receptor (1), it is
related in its amino acid sequence to the calpactins, a family
of cytoplasmic calcium-binding proteins (4). Within placenta
the 34-kDa polypeptide is biosynthesized by the embryonally
derived trophoblasts. It is expressed on the plasma mem-
branes of both mononuclear and multinuclear trophoblasts.
The expression of the protein is developmentally regulated-
i.e., trophoblasts from first trimester placenta immunostain
far more strongly for the protein than those from term
placenta (2). The protein is also expressed in a cell-specific
manner in certain adult endocrine and exocrine tissues, such
as testis, thyroid, adrenal cortex, pancreas, and stomach,
suggesting a role in differentiated cell function (3).
In the trophoblasts, the membrane-association of the
34-kDa protein is mediated through two types of interactions
(1): (i) a fraction of the membrane-bound protein is only
peripherally associated-i.e., it can be released by high-salt
treatment (this property has been useful in purification ofthe
protein); and (ii) the remainder show the characteristics of
MATERIALS AND METHODS
Antibody. Antibody to the 34-kDa growth factor was
generated as described (2). Rabbits were immunized with a
pure, homogeneous preparation of the 34-kDa placental
protein. The specificity of the antibody for the 34-kDa protein
was established by immunoprecipitation, immunoblot analy-
sis, and other analyses (2). The epitopes recognized by this
antibody are not carried by other cellular proteins or by a host
of other circulating hormones and growth factors.
Isolation of Cytotrophoblasts. Cytotrophoblasts were iso-
lated from term and first-trimester human placenta as de-
scribed (7). The isolated cells were plated (5 x 10' cells per
16-mm dish) in Dulbecco's modified Eagle's (DME) medium
containing 20%o fetal bovine serum and were used in exper-
iments 4 hr later.
Labeling of Cytotrophoblasts with [35S]Methionine. Four
hours after plating, the cytotrophoblasts were washed with
DME medium containing 4 ,uM methionine and then incu-
bated at 37°C for 16 hr in the same medium containing
[35Slmethionine (100 ,uCi/ml; 3.5 mCi/,umol, Amersham; 1
Ci = 37 GBq) and 2.5% dialyzed fetal bovine serum. After
incubation, the cells were either immediately lysed and
subjected to immunoprecipitation or were first treated with
lipases and then subjected to lysis and immunoprecipitation.
Abbreviations: PtdCho, phosphatidylcholine; Ptdlns, phosphatidyl-
inositol.
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Treatment of Cytotrophoblasts with Lipases. Cytotropho-
blasts (either unlabeled or 35S-labeled) in 16-mm dishes were
washed with DME medium and then incubated at 30'C for 1
hr in 100 Al ofDME medium containing bovine serum albumin(0.1 mg/ml) with or without one of the following additions:
phosphatidylinositol (PtdIns)-specific phospholipase C (10
Ag/ml) purified from S. aureus (8); phospholipase C (5 units/
ml) from Bacillus cereus (Sigma); or phospholipase A2 (5 units/
ml) (Sigma).
After the treatment, the medium was carefully taken out,
briefly centrifuged to remove any detached cells, and then
subjected to immunoprecipitation (in the case of biosynthet-
ically labeled cells) or to immunoblot analyses (in the case of
unlabeled cells). The unlabeled medium samples for immu-
noblot analysis were subjected to trichloroacetic acid pre-
cipitation (0.5 ml of 10% trichloroacetic acid and 10 j1 of
insulin at 1 mg/ml as a carrier protein), followed by solubi-
lization in NaDodSO4 sample buffer prior to analysis.
The cells remaining in the dishes were combined with
those detached off the dish and then treated as follows: (i)
the biosynthetically labeled cells were lysed with 50 1ul of a
buffer containing 1% Triton X-100, 2 mM phenylmethylsul-
fonyl fluoride, 2 mM benzamidine, 25 .ug of aprotinin per ml,
0.15 M NaCl, and 10 mM sodium phosphate buffer (pH
7.4), and the lysate was subjected to immunoprecipitation as
described below; (ii) the unlabeled cells were lysed with 50
Al ofNaDodSO4 sample buffer and subjected to immunoblot
analyses as described below.
Immunoprecipitation. The samples were treated first with
240 ,ug of rabbit nonimmune IgG at 4°C for 1 hr and then with
10 mg of Staphylococcus aureus at 4°C for 30 min. The
resultant supernatant was subjected to immunoprecipitation
by using 25 ,ug of rabbit anti-34-kDa peptide immune IgG (or
25 ug of nonimmune rabbit IgG) and 10 mg of washed S.
aureus as described (2) and then was analyzed by NaDod-
S04 gel electrophoresis and fluorography (9).
Electrophoretic Immunoblotting Method. The cell or me-
dium samples were subjected to NaDodSO4/PAGE under
reducing conditions (9). The electrophoretically separated
proteins were electrophoretically transferred to nitrocellu-
lose sheets. The sheets were treated with anti-34-kDa pep-
tide antibody, a second antibody, and "2'I-labeled protein A
as described (2) and then were washed, dried, and subjected
to autoradiography.
Labeling of Cytotrophoblasts with [3HlMyristic Acid. At 4
hr after plating, the cytotrophoblasts were incubated at 37°C
for 16 hr with [3H]myristic acid (100 uCi/ml; 20 Ci/mmol,
New England Nuclear) in DME medium containing 2.5%
dialyzed fetal bovine serum. After incubation, the cells were
lysed, and the lysates from labeled cells were incubated at
30°C for 1 hr with or without 10 units of phospholipase C per
ml in a buffer containing 20mM Hepes (pH 7.4), 0.5% Triton
X-100, 2 mM phenylmethylsulfonyl fluoride and 20 ,ug of
leupeptin per ml. The samples were then subjected to
immunoprecipitation, NaDodSO4/PAGE and fluorography.
Lipase Treatment of Placental Membranes. Syncytiotro-
phoblast membranes were isolated from term human pla-
centa as described (1). Membranes (3 ,ug of protein) were
salt-treated by stirring at 4°C for 2 hr with 20 ul of 3 M
NaCl/20 mM Hepes, pH 7.4. The salt treatment results in
the removal of <2% of total membrane proteins but releases
>30%o of the membrane-associated 34-kDa protein. The salt-
treated membranes were washed once with 1 ml of 20 mM
Hepes (pH 7.4) and then incubated at 30°C for 1 hr in 20 Al of
20 mM Hepes containing 0.1 mg of bovine serum albumin per
ml (pH 7.4) with or without 5 units ofphospholipase C from B.
cereus (Sigma) per ml. At the end of the incubation, the
membrane suspensions were transferred to ice, diluted with
25 1LI of 20 mM Hepes (pH 7.4), and then centrifuged. The
supernates and pellets obtained were boiled with NaDodSO4
sample buffer and subjected to immunoblot analysis as de-
scribed above.
RESULTS
Release of the Immunoreactive 34-kDa Protein from Intact
Cells by Phospholipase C. Cytotrophoblasts from both term
and first-trimester placenta can biosynthesize a 34-kDa
polypeptide that is specifically recognized by the anti-34-
kDa peptide antibody (Fig. 1). It should be noted that cells
from first-trimester placenta are far more active in biosyn-
thesis of the protein than the term placental cells are (Fig. 1).
These results agree with our earlier immunohistochemical
observations (2, 3) and indicate that the expression of this
protein in placenta is developmentally regulated. Since the
first trimester cell type is a good system for studies on the
34-kDa protein, it was used for the experiments described
here.
To test for the possibility of large posttranslational modi-
fications, pulse-chase experiments were conducted (7). The
results indicate that biosynthesis in neither cell type (term or
first trimester) is associated with any gross posttranslational
modification that would produce a change in mobility during
NaDodSO4/PAGE (data not shown).
To test whether the 34-kDa protein in cytotrophoblasts
undergoes a lipid addition that could account for its anchor-
age in the membrane, we tested the effect of phospholipase
C and phospholipase A2. Biosynthetically labeled first-
trimester cytotrophoblasts were used in these studies. Fig. 2
Left shows that phospholipase C but not phospholipase A2
can release the immunoreactive 34-kDa protein from intact
cells, suggesting that the protein may be anchored to the
membrane through a posttranslationally added phospholipid.
The phospholipase C-mediated release of the 34-kDa
protein into medium was not accompanied by the release of
the transmembrane EGF receptor (not shown), indicating
Term
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FIG. 1. Synthesis of the 34-kDa polypeptide by purified cyto-
trophoblasts from term and first-trimester human placenta. The
indicated numbers of cytotrophoblasts were labeled for 4 hr with
[35S]methionine, and the lysates from labeled cells were subjected to
immunoprecipitation with anti-34-kDa antibody (lanes AB) or non-
immune rabbit IgG (lanes NI). K, kDa.
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FIG. 2. Release of biosynthetically labeled 34-kDa protein from intact cytotrophoblasts by phospholipase C. [35S]Methionine-labeled
first-trimester cytotrophoblasts were treated with phospholipase C (PLC) or phospholipase A2 (PLA2). The radioactivity released into the
medium (lanes "Med.") and the cell-associated radioactivity (lanes "Cell") were subjected to immunoprecipitation with anti-34-kDa antibody
(lanes Ab) or nonimmune rabbit IgG (lanes Ni). (Left) Immunoprecipitation analysis of medium-released and cell-associated proteins after
treatment of cells with lipases. (Right) NaDodSO4/PAGE analysis of total radioactive proteins released into the medium (lanes Med.) by control
and phospholipase C-treated cells (no immunoprecipitation was performed). The figure also shows the total protein radioactivity remaining
associated with the cells (lanes Cell) after the treatment.
that this lipase-treatment does not release proteins that are
anchored to the membrane through hydrophobic protein
segments. An examination of the total medium-released 35S-
labeled proteins showed some differences in profile, indicat-
ing that a number of proteins are released by phospholipase C
treatment (Fig. 2 Right). However, there was no gross differ-
ence (i.e., >1.5-fold) in the total protein radioactivity released
from control and phospholipase C-treated cells (Fig. 2 Left),
indicating that the lipase treatment does not bring about
leakage of intracellular components.
The B. cereus-derived phospholipase C (Sigma) used for
the experiment in Fig. 2 contains phosphatidylcholine (Ptd-
Cho)-specific phospholipase C as the major component and
a PtdIns-specific phospholipase C as a minor component. To
determine whether the PtdCho-specific component is re-
sponsible for the release of the 34-kDa protein, we tested the
effect of phenanthroline. Phenanthroline is a strong inhibitor
of PtdCho-specific phospholipase C (10), but has no effect on
PtdIns-specific phospholipase C. The phospholipase C-
mediated release of the 34-kDa protein was found to be
unaffected by phenanthroline (data not shown). To test
whether the phospholipase C-mediated release of the 34-kDa
protein is indeed due to a PtdIns-specific phospholipase C,
we examined the effects of a purified preparation of PtdIns-
specific phospholipase C from S. aureus (8). Fig. 3 shows
that the pure PtdIns-specific phospholipase C can release the
immunoreactive 34-kDa protein from intact cytotropho-
blasts. These results are consistent with the idea that the
34-kDa protein is anchored to the membrane through an
inositol phospholipid.
We next tested whether B. cereus-derived phospholipase
C and B. aureus derived PtdIns-specific phospholipase C act
at similar sites. We found that the S. aureus PtdIns-specific
phospholipase C treatment of cells that were previously
treated with B. cereus phospholipase C did not bring about
any additional release of the immunoreactive 34-kDa pro-
tein, but the reverse treatment (i.e., incubation with B. cereus
phospholipase C following a treatment with S. aureus PtdIns-
specific phospholipase C) resulted in release of additional
34-kDa protein (data not shown). These results indicate that a
fraction (-25%) of membrane-anchored 34-kDa protein is
released by both S. aureus PtdIns-specific phospholipase C
and B. cereus phospholipase C, but there is an additional
fraction (p40%o of the total) that is released only by B. cereus
phospholipase C and not by S. aureus PtdIns-specific phos-
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FiG. 3. Release of the 34-kDa protein from intact cytotropho-
blasts by PtdIns-specific phospholipase C (PLC). At 16 hr after
plating, first-trimester cytotrophoblasts in 16-mm dishes were
treated with 10 jig of pure PtdIns-specific phospholipase C per ml.
The medium-released (lanes Med.) and cell-associated proteins (lanes
Cell) from control and PtdIns-specific phospholipase C-treated plates
were subjected to immunoblot analysis as described. K, kDa.
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pholipase C. This extra releasing activity of B. cereus phos-
pholipase C is unrelated to its PtdCho-specific phospholipase
C activity (see the previous paragraph). We do not know
whether this difference between S. aureus PtdIns-specific
phospholipase C and B. cereus phospholipase C is due to
heterogeneity of the lipid anchor or due to differences in
accessibility of the anchoring phospholipid to enzymes from
different species.
Acylation of the 34-kDa Protein. We next demonstrated
that [PH]myristate is biosynthetically incorporated into the
34-kDa protein (Fig. 4). Identity of the labeled 34-kDa pro-
tein was confirmed by immunoprecipitation analysis (Fig. 4).
We investigated the nature of the fatty acid-protein attach-
ment. The radioactivity associated with the [3H]myristate-
labeled 34-kDa protein was labile to phospholipase C treat-
ment-i.e., the fluorogram of the digested and undigested
[3H]myristate-labeled 34-kDa protein shows loss of cova-
lently bound label by phospholipase C digestion. In contrast,
similar phospholipase C digestion of the [35S]methionine-
labeled 34-kDa protein in solution failed to release radioac-
tivity from the protein (not shown), discounting the likeli-
hood that the observed loss of [3H]myristate label is due to
a contaminating protease activity in the phospholipase C
preparation. These results indicate that the fatty acid is
bound to the 34-kDa protein in the form of phospholipid.
Biological Activity of the 34-kDa Protein Released by Phos-
pholipase C. To test the biological activity of the phospholi-
pase C-released protein, we used purified plasma mem-
branes from placental trophoblasts. The results in Fig. 5
show that a substantial fraction of the salt-resistant 34-kDa
protein is released from membrane by phospholipase C. The
release showed the following characteristics (data not
shown): (i) the phospholipase C-mediated release was not
inhibited by phenanthroline, a strong inhibitor of PtdCho-
specific phospholipase C; (ii) the release of the 34-kDa
protein was not accompanied by release of the EGF recep-
tor, a prototypical transmembrane protein; and (iii) no
release was observed after treatment with phospholipase A2.
Thus, the characteristics of phospholipase C-mediated re-
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FIG. 4. [3H]Myristic acid labeling of the 34-kDa protein, and
loss of label by digestion with phospholipase C (PLC). First-
trimester cytotrophoblasts were labeled with [3H]myristic acid. The
phospholipase C-induced loss of radiolabel from the 34-kDa protein
was specific for the [3H]myristate label. In a parallel experiment in
which [5S]methionine-labeled 34-kDa protein was subjected to an
identical phospholipase C treatment, no loss of radiolabel was ob-
served.
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FIG. 5. Phospholipase C (PLC) specifically releases the salt-
resistant fraction of the protein from membranes. Syncytiotropho-
blast membranes from human term placenta were salt-treated as
described. This resulted in the release of about 30%o of the immu-
noreactive 34-kDa protein. The treated membranes were washed
and then incubated at 300C for 1 hr with or without phospholipase C.
The supernatant (lanes S) and pellet (lanes P) fractions were subjected
to immunoblot analysis. K, kDa.
lease of the 34-kDa protein from isolated membranes are
very similar to those of its release from intact cells.
The results in Fig. 5 show that the salt-resistant 34-kDa
protein released by phospholipase C is antigenically identical
to the salt-released 34-kDa protein. To test for its biological
functionality, we examined the phospholipase C-released
protein for its receptor binding activity. The 34-kDa protein
released by phospholipase C digestion of placental mem-
branes competes well with authentic "25I-labeled 34-kDa
protein for binding to its receptor (Fig. 6). The ability to
compete (i.e., affinity of the phospholipase C-released pro-
tein for the receptor) is comparable to that of the authentic
(i.e., salt-released) 34-kDa- protein.
DISCUSSION
The experiments described here have produced the follow-
ing results. (i) Phospholipase C can release the immunoreac-
tive 34-kDa protein from both intact cytotrophoblasts and
isolated trophoblastic membranes; the salt-resistant fraction
of the protein is specifically released. (ii) The identity of the
released protein with the 34-kDa growth factor has been
established by both immunologic and receptor-binding as-
says. (iii) There is biosynthetic incorporation of [3H]myristic
acid into the 34-kDa protein, and the incorporated label is
labile with phospholipase C treatment. (iv) The involvement
of an inositol phospholipid in membrane anchorage is sug-
gested by the fact that pure PtdIns-specific phospholipase C
can release the protein.
These results suggest that the 34-kDa protein is anchored
to the membrane via a posttranslationally added phospho-
lipid. Recent studies show that anchorage of proteins' to
membranes is not absolutely dependent upon the presence of
a hydrophobic protein segment; anchorage may be mediated
through posttranslationally added lipids (5, 6). Fatty acid
acylation has been demonstrated in a number of membrane
proteins. In some cases, a myristic -acid that is amide-linked
to the a-amino group on the N-terminal glycine residue is
responsible for membrane anchorage (11). In other cases a
phospholipid (PtdIns with myristic acid as the acyl group) is
covalently attached through an intervening glycan structure
to an amino acid in the protein (5, 6). Examples in the latter
category include the Thy-1 antigen (12), the T cell-activating
protein (13), alkaline phosphatase (14), 5'-nucleotidase (15),
acetylcholinesterase (16), decay-accelerating factor (17),
120-kDa neural cell adhesion molecule (18), and the surface
proteins of trypanosomes (19) and leishmania (20). These
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FIG. 6. Receptor-binding activity of the phospholipase C-
released 34-kDa protein. Salt-treated placental membranes (1 mg of
protein) were incubated at 30'C for 1 hr with or without 10 units of
phospholipase C per ml in 250 Al of 50 mM Hepes (pH 7.4)
containing 0.2 mM phenylmethylsulfonyl fluoride and 10 jzg of
leupeptin per ml. The suspension was cooled in ice and centrifuged
at 100,000 x g for 1 hr. The supernates obtained were subjected to
gel-filtration on a TSKG3000SW column (0.8 x 30 cm) in a LKB
bioseparation system. Fractions corresponding to elution volumes
of 9.5-10.8 ml (the position of the 34-kDa protein) were collected
and concentrated by ultrafiltration. This procedure yields a prepa-
ration of the 34-kDa protein that is -90%o pure and free of phospho-
lipase C and major membrane-released protein contaminants. The
preparation in 300 ,ul of Earle's balanced salt solution containing 1
mg of bovine serum albumin per ml (EBSS-BSA) was tested for
competitive inhibition of 125I-labeled 34-kDa protein binding to
mouse 3T3 cells as described (1). Briefly, the cell monolayers (in
16-mm dishes) were incubated at 40C for 2 hr in 200.ul of EBSS-BSA
containing S nM 125I-labeled 34-kDa protein (50,000 cpm/ng) with or
without one of the following additions: (i) the purified and concen-
trated supernate from phospholipase C-treated membranes (A), (ii)
the purified and concentrated supernate from control-treated mem-
branes (e), and (iii) pure unlabeled 34-kDa protein isolated from the
salt extract of membrane (x). At the end of incubation, cell-
associated radioactivity was determined as described (1). The values
plotted represent specific binding. Nonspecific binding (-2200 cpm)
was determined in the presence of 2.5 p.M unlabeled 34-kDa protein.
PtdIns-anchored proteins are all on the surface. In the case
of the 34-kDa growth factor, an extracellular location is
indicated by the fact that phospholipase C can release the
protein from intact cells (Fig. 2 Left). Surface radioiodina-
tion studies also indicate an external location for the protein
(data not shown).
The studies described here are consistent with the utiliza-
tion by the 34-kDa protein of a covalently attached PtdIns as
the membrane anchor. However it should be noted that
PtdIns-specific phospholipase C does not release all of the
immunoreactive 34-kDa protein from membranes. We do not
know whether this resistance is due to masking of the phos-
pholipid or the presence of other lipid anchors. A similar or
higher degree of resistance to Ptdlns-specific phospholipase C
has been noted for a number of other PtdIns-anchored pro-
teins-i.e., 5'-nucleotidase (15), acetylcholinesterase (16), and
decay-accelerating factor (17).
Apart from anchoring proteins to membranes, the func-
tions of this particular anchoring mechanism are unknown.
Several questions are raised by this model and remain to be
answered. (i) Is the ratio of salt-released to salt-resistant
34-kDa protein in trophoblasts dependent upon the state of
activation of an anchor-degrading phospholipase (21) similar
to that described (22) as participating in insulin action? (ii) Is
the release of the 34-kDa protein from its membrane anchor
necessary for acquisition of receptor-binding activity, and if
so, does the release lead to salt-sensitive binding to mem-
brane through specific receptors? (iii) Alternatively, if the
membrane-anchored protein itself is competent to bind to
receptors, could it mediate intercellular adhesion by this
mechanism?
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